Randomized, Global, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Vedolizumab IV for the Treatment of Primary Sclerosing Cholangitis, With Underlying Inflammatory Bowel Disease
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 19 May 2017
At a glance
- Drugs Vedolizumab (Primary)
- Indications Primary sclerosing cholangitis
- Focus Therapeutic Use
- Sponsors Takeda
- 18 May 2017 This trial has been discontinued in Sweden.
- 22 Apr 2017 This trial has been discontinued in Poland (end date: 23 Feb 2017).
- 01 Apr 2017 Trial has been discontinued in Belgium (End date:2017-02-23) as per European Clinical Trials Database record.